Our top pick for
iBio, Inc is a biotechnology business based in the US. iBio shares (IBIO) are listed on the NYSE MKT and all prices are listed in US Dollars. iBio employs 55 staff and has a trailing 12-month revenue of around USD$1.3 million.
|52-week range||USD$0.05 - USD$7.45|
|50-day moving average||USD$2.4026|
|200-day moving average||USD$2.0165|
|Wall St. target price||USD$3.1|
|Dividend yield||N/A (0%)|
|Earnings per share (TTM)||USD$-0.943|
The value of any investment can go up or down depending on news, trends and market conditions. We are not investment advisers, so do your own due diligence to understand the risks before you invest.
The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.
This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.
|1 week (2020-09-17)||-100.00%|
|1 month (2020-08-27)||-100.00%|
|3 months (2020-06-26)||-100.00%|
|6 months (2020-03-27)||-100.00%|
|1 year (2019-09-27)||-100.00%|
|2 years (2018-09-27)||-100.00%|
|3 years (2017-09-27)||-100.00%|
|5 years (2015-09-25)||-100.00%|
|Revenue TTM||USD$1.3 million|
|Gross profit TTM||USD$2 million|
|Return on assets TTM||-23.99%|
|Return on equity TTM||-320.62%|
|Market capitalisation||USD$336.6 million|
TTM: trailing 12 months
There are currently 16.0 million iBio shares held short by investors – that's known as iBio's "short interest". This figure is 73.6% up from 9.2 million last month.
There are a few different ways that this level of interest in shorting iBio shares can be evaluated.
iBio's "short interest ratio" (SIR) is the quantity of iBio shares currently shorted divided by the average quantity of iBio shares traded daily (recently around 34.8 million). iBio's SIR currently stands at 0.46. In other words for every 100,000 iBio shares traded daily on the market, roughly 460 shares are currently held short.
However iBio's short interest can also be evaluated against the total number of iBio shares, or, against the total number of tradable iBio shares (the shares that aren't held by "insiders" or major long-term shareholders – also known as the "float"). In this case iBio's short interest could be expressed as 0.09% of the outstanding shares (for every 100,000 iBio shares in existence, roughly 90 shares are currently held short) or 0.112% of the tradable shares (for every 100,000 tradable iBio shares, roughly 112 shares are currently held short).
Such a low SIR usually points to an optimistic outlook for the share price, with fewer people currently willing to bet against iBio.
Find out more about how you can short iBio stock.
We're not expecting iBio to pay a dividend over the next 12 months.
iBio's shares were split on a 1:10 basis on 11 June 2018. So if you had owned 10 shares the day before before the split, the next day you'd have owned 1 share. This wouldn't directly have changed the overall worth of your iBio shares – just the quantity. However, indirectly, the new 900% higher share price could have impacted the market appetite for iBio shares which in turn could have impacted iBio's share price.
Over the last 12 months, iBio's shares have ranged in value from as little as $0.05 up to $7.45. A popular way to gauge a stock's volatility is its "beta".
Beta is a measure of a share's volatility in relation to the market. The market (NYSE MKT average) beta is 1, while iBio's is -5.9482. This would suggest that iBio's shares have been inversely-correlated to the average (for this exchange) – so when the broader market trended up or down, iBio has bucked the trend.
iBio, Inc., a biotechnology company, provides product development and manufacturing services to clients, collaborators, and third-party customers in the United States and internationally. The company's services cover the stages of pre-clinical development, regulatory approval, commercial product launch, and on-going commercial phase requirements. Its lead therapeutic candidate is IBIO-CFB03 for the treatment of systemic scleroderma, idiopathic pulmonary fibrosis, and other fibrotic diseases. The company is also developing vaccine candidates for third parties. It has a license agreement with the University of Natural Resources and Life Sciences, Vienna; a strategic relationship with Beijing CC-Pharming Ltd.; and collaboration agreements with AzarGen Biotechnologies (Pty) Ltd, The Texas A&M University System, and Fraunhofer Center for Molecular Biotechnology. In addition, the company offers a range of product and process development, analytical, and manufacturing services. iBio, Inc. is headquartered in New York, New York.
finder.com is an independent comparison platform and information service that aims to provide you with the tools you need to make better decisions. While we are independent, the offers that appear on this site are from companies from which finder.com receives compensation. We may receive compensation from our partners for placement of their products or services. We may also receive compensation if you click on certain links posted on our site. While compensation arrangements may affect the order, position or placement of product information, it doesn't influence our assessment of those products. Please don't interpret the order in which products appear on our Site as any endorsement or recommendation from us. finder.com compares a wide range of products, providers and services but we don't provide information on all available products, providers or services. Please appreciate that there may be other options available to you than the products, providers or services covered by our service.